PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Gross profit growth 1.25-1.5x GNPX's 2.95%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
8.25%
EBIT growth above 1.5x GNPX's 3.10%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
8.25%
Operating income growth above 1.5x GNPX's 3.10%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
12.55%
Net income growth above 1.5x GNPX's 2.91%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
15.52%
EPS growth 1.25-1.5x GNPX's 12.70%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
15.52%
Diluted EPS growth 1.25-1.5x GNPX's 12.70%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
3.21%
Share reduction more than 1.5x GNPX's 11.24%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
3.21%
Diluted share reduction more than 1.5x GNPX's 11.21%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
18.46%
OCF growth under 50% of GNPX's 41.59%. Michael Burry might suspect questionable revenue recognition or rising costs.
18.52%
FCF growth under 50% of GNPX's 41.47%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.04%
Positive long-term OCF/share growth while GNPX is negative. John Neff would see a structural advantage in sustained cash generation.
77.11%
5Y OCF/share CAGR above 1.5x GNPX's 18.45%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-27.06%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
72.83%
Net income/share CAGR 1.25-1.5x GNPX's 60.52%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
70.62%
5Y net income/share CAGR above 1.5x GNPX's 10.23%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-36.68%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
109.68%
Equity/share CAGR of 109.68% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-48.78%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-45.28%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while GNPX invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Negative asset growth while GNPX invests at 4.60%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-20.44%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-5.39%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
4.88%
R&D dropping or stable vs. GNPX's 16.08%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-40.17%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.